Glenmark Pharma surged 15% to a record high after signing a $1.9 billion global licensing deal with AbbVie for its cancer drug ISB 2001. Analyst Akhilesh Jat said the move validates Glenmark's R&D strength and opens new global revenue streams. Technicals show bullish momentum above ₹1,800-1,600 support. YTD gains now stand at 35%.